Answers are grounded in this paper and cite their sources.
T-cell engineering has emerged as a powerful immunotherapeutic strategy, particularly in oncology, and fundamentally relies on the design and optimization of gene delivery technologies. CAR-T cell therapy, TCR engineering, and other innovative approaches are considered as part of this concept. This review provides an integrated framework linking gene delivery strategies to the core principles of T cell engineering. Both viral and non-viral vectors play complementary roles in T cell engineering. Viral platforms provide high transduction efficiency and stable gene expression, whereas non-viral platforms offer improved safety, scalability, and tunable design flexibility. Owing to their tunable physicochemical properties, biocompatibility, and versatile surface functionality, nano-based vectors such as lipid-, polymer-, and nanoparticle-based systems can enable efficient gene encapsulation and controlled release, thereby enhancing transfection efficiency and therapeutic outcomes. This review comprehensively explores the paradigm shift toward in vivo gene delivery and highlights the emerging role of artificial intelligence in guiding target discovery, receptor design, and safety optimization. Together, these insights outline a forward-looking roadmap for developing intelligent, efficient, and clinically translatable T cell therapies.
No takes yet. Share an insight, caveat, or question.
Makvandi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: